LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
LIGAND PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$297.28+1.74 (+0.59%)
Close on Oct 19, 2026
- Market cap
- $6.49B
- P/E (TTM)
- 31.6
- Dividend yield
- –
Share price
+$115.63 (+63.66%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
LIGAND PHARMACEUTICALS INC grew revenue 54.9% to $290.54M over the twelve months to Jun 30, 2026. Free cash flow was $131.44M, up 145.1% from a year earlier.
Revenue
$290.54M
+54.9% vs. a year earlier
Operating income
$94.73M
TTM Q2 2026
Free cash flow
$131.44M
+145.1% vs. a year earlier
EPS, diluted
$9.40
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $6.49B
- P/E ratio
- 31.6
- Price to sales
- 22.34
- Price to book
- 6.71
- Dividend yield
- –
- Free cash flow yield
- 2.02%
Fundamentals
- Revenue
- $290.54M
- Net income
- $197.22M
- EPS, diluted
- $9.40
- Free cash flow
- $131.44M
- Book value per share
- $44.31
- Diluted shares
- 22M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$290.54M+54.9% YoY
Gross profit
–
Operating income
$94.73M
Net income
$197.22M
EPS, diluted
$9.40
Free cash flow
$131.44M+145.1% YoY
Reported periodTrailing twelve months